Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Dec-23
- 19-Sep-24
- 17-Oct-24
- 14-Nov-24
- 21-Nov-24
Select bar for recommendation details.
Recommendations | 21-Nov-24 | |
---|---|---|
Buy | 7 | |
Outperform | 8 | |
Hold | 1 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 16 analysts offering 12 month price targets for Viridian Therapeutics Inc have a median target of 41.00, with a high estimate of 61.00 and a low estimate of 22.00. The median estimate represents a 108.97% increase from the last price of 19.62.
High | 210.9% | 61.00 |
Med | 109.0% | 41.00 |
Low | 12.1% | 22.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate | -6.06% |
Average growth rate | +23.24% |
More ▼
Revenue history & estimates in USD
Average growth rate | +4.86% |
Average growth rate | -4.19% |
More ▼